Pharmaceuticals

Merck (NYSE: MRK) and ARIAD Pharmaceuticals, Inc., (NASDAQ: ARIA), today announced that the European Medicines Agency has completed its administrative validation process for the regulatory application for ridaforolimus, an investigational oral mTOR inhibitor developed for the treatment of...

by Stephen Leeb, editor Leeb's Income Performance letter In today's uncertain investment world, the health care sector should play an important role in everyone's portfolio. We're buying Abbott Labs (ABT), which offers conservative investors solid growth and income all in one capsule.

On CNBC's Fast Money, Tim Seymour recommended a long position in Petroleo Brasileiro SA (ADR) (NYSE: PBR). Petroleo Brasileiro SA (ADR) (PBR) gained 1.24%, and it closed at $29.37. Guy Adami believes that Forest Laboratories, Inc. (NYSE: FRX) is a buy. Forest Laboratories, Inc. (FRX) fell 2.44%...

Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it is terminating its research program and collaboration related to the development of axomadol. Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009. "As a leader in...

Exterran Holdings (NYSE: EXH) +6.18 on heavier than average volume. Diana Shipping (NYSE: DSX) +7.96% on heavier than average volume. Valeant Pharmaceuticals (NYSE: VRX) +5.79 on average daily volume Popular (NASDAQ: BPOP) +5.07% on lower than average daily volume. Pandora Media (NYSE: P) 5.15...

Alexza Pharmaceuticals (NASDAQ: ALXA) has recently submitted a new NDA to the FDA for their Staccato loxapine drug (AZ-004), in the hopes of having it approved for treatment of agitation within schizophrenia and bipolar patients. Alexza received a CRL for the drug in October 2010, as the FDA cited...

Investors Bancorp Inc (NASDAQ: ISBC) announced its plans to acquire Brooklyn Federal Bancorp Inc (NASDAQ: BFSB) for $0.80 per share or around $10.3 million in the aggregate. Shares of Cyanotech Corporation (NASDAQ: CYAN) rose about0.5% as the company named Jole Deal as Chief Financial Officer,...

Goldman Sachs is out with a research note this morning, where it suggests that traders buy calls on Pfizer (NYSE: PFE) ahead of the August 28th data release. Goldman's analyst expects Apixaban (Eliquis, an anticoagulant) annual sales to reach $3-$4 bn. Given the top-line release for this drug met...

J.P. Morgan has published a research report on Perrigo Company (NASDAQ: PRGO), raising the price target by $6. In the report, J.P. Morgan wrote, "We are modestly increasing our sales and EPS stimates following Perrigo's FY4Q/11 results and FY2012 guidance. The company reported a relatively in-...

Jole Deal has been appointed as Chief Financial Officer, Vice President of Finance and Administration, Treasurer and Secretary by the Board of Directors of Cyanotech Corporation (Nasdaq: CYAN). She succeeds Deanna Spooner, who resigned. “We greatly appreciate Deanna's contributions to building...

Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Endo Pharmaceuticals in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Frovatriptan Succinate EQ, 2.5 mg base...

This is your Benzinga news summary and traders' outlook for Wednesday, August 17, 2011, covering headlines from overnight and Wednesday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are trading higher. At last check, Dow futures are up about 40 points and the U.S...

JP Morgan has raised the price target on Perrigo Company (NASDAQ: PRGO) from $82 to $88 and maintains its Neutral rating.

On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Cisco Systems (NASDAQ: CSCO) is “OK. They're no longer in the doghouse." For Mylan Laboratories (NASDAQ: MYL), he said, "No, no, if Teva Pharmaceutical (NASDAQ: TEVA) can't make any money right now, how can this one?" For Penn...

Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED ® (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty. CPP is a condition that...